Century Therapeutics
VerifiedDeveloping novel allogeneic iPSC-derived natural killer (NK) and T cell products with the potential to overcome many limitations of earlier generation cell therapies.
Launch date
Employees
Market cap
$196m
Net debt
$125m
Enterprise valuation
$72m (Public information from May 2024)
Share price
$3.04 IPSC
Philadelphia Pennsylvania (HQ)
Deals in current and previous year:
Authorizing premium user...